RxDoctor Payments Data

Jose Gonzalez, MD

Neurology · Miami, FLNPI 1881950905

Payments from drug & device makers

$11,607in general payments, 2019–2025

Across 436 payments — averaging $26.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • EMD Serono, Inc.$2K
  • SK Life Science, Inc.$745
  • Amneal Pharmaceuticals LLC$672
  • GE HealthCare$630
  • Novartis$623
  • plus $5K from 43 others
$1,865in research payments, 2019–2025

Across 1 payment — averaging $1865.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K

What the payments were for

  • Food & beverage$11,26397%
  • Education$3443%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,607 in reported general payments places this provider in the 65th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$46,009
Medicare patients
101
Services billed
267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab26$262,701
RytaryCarbidopa/Levodopa164$126,646
Avonex Pen (4 Pack)Interferon Beta-1a12$115,366
NeuproRotigotine42$36,892
Aimovig AutoinjectorErenumab-Aooe35$35,418
XcopriCenobamate27$32,040
UbrelvyUbrogepant21$31,667
Memantine Hcl856$25,836
QuliptaAtogepant23$25,659
NamzaricMemantine Hcl/Donepezil Hcl12$20,117
Nurtec OdtRimegepant Sulfate14$18,445
Emgality PenGalcanezumab-Gnlm23$16,325
Entacapone44$8,552
ExelonRivastigmine11$7,592
RivastigmineRivastigmine Tartrate84$7,339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$672$130,113224 claims
AbbVieUbrelvy, Qulipta, Namzaric$2,069$77,44356 claims
UCB, Inc.Neupro$369$36,89242 claims
SK Life Science, Inc.Xcopri$745$32,04027 claims
PfizerNurtec Odt$83$18,44514 claims
NovartisExelon$623$7,59211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,434 neurology providers in Florida.

Other neurology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →